NR 565 Advanced Pharmacology Midterm Exam Review | Chamberlain (2026/2027)
NR 565 / NR565 ADVANCED PHARMACOLOGY MIDTERM EXAM
REVIEW | ALREADY RATED A | LATEST, 2026/2027 |
CHAMBERLAIN COLLEGE
Chamberlain University — College of Nursing
Aligned with NR565 Advanced Pharmacology Course Syllabus, AACN Essentials of Master's Education, and
Advanced Practice Pharmacotherapeutics Standards (2026/2027 Edition)
Total Questions: 130 | Sections: 11 | Cognitive Mix: 25% Recall, 50% Application, 25% Analysis
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: An advanced practice nurse is reviewing a drug with a high hepatic extraction ratio
given orally. Which characteristic best describes the clinical consequence of this
property?
A. Oral bioavailability is low because of extensive hepatic first-pass metabolism;
changes in hepatic blood flow or enzyme activity can markedly alter serum
concentrations [CORRECT]
B. The drug is completely absorbed and achieves predictable serum levels regardless of hepatic
function
C. The drug is eliminated primarily unchanged by the kidney and requires no hepatic
consideration
D. Half-life is prolonged because hepatic enzymes are saturated at therapeutic doses
Correct Answer: A
Rationale: High-extraction-ratio drugs (e.g., propranolol, morphine, lidocaine, nitroglycerin) are
extensively removed by the liver during first-pass through the portal circulation, resulting in low oral
bioavailability. Changes in hepatic blood flow (e.g., heart failure) or enzyme activity (CYP
inducers/inhibitors) can markedly alter serum concentrations, requiring dose adjustment.
Q2: A drug has a half-life of 10 hours. Approximately what percentage of the drug
remains in the body 30 hours after the last dose (assuming first-order kinetics)?
A. 50% (one half-life)
B. 25% (two half-lives)
C. 12.5% (three half-lives) [CORRECT]
D. 6.25% (four half-lives)
Correct Answer: C
Rationale: After one half-life 50% remains, after two half-lives 25% remains, after three half-lives
12.5% remains, after four half-lives 6.25% remains. Thirty hours represents three half-lives for a drug
with a 10-hour half-life (30 ÷ 10 = 3). Steady state is achieved in approximately 4–5 half-lives.
Q3: Which statement best explains why a drug with high protein binding may require
cautious co-administration with another highly protein-bound drug?
A. Displacement from binding sites can transiently increase the free,
pharmacologically active fraction, potentially increasing effect or toxicity
[CORRECT]
B. Protein binding increases renal filtration of the drug
Chamberlain University — College of Nursing Page 1
,NR 565 Advanced Pharmacology Midterm Exam Review | Chamberlain (2026/2027)
C. Protein-bound drug is more readily metabolized by the liver
D. Protein binding eliminates the risk of drug interactions
Correct Answer: A
Rationale: Only unbound (free) drug is pharmacologically active and available for metabolism and
elimination. When two highly protein-bound drugs compete for binding sites (e.g., warfarin +
sulfamethoxazole), displacement can transiently raise the free fraction and increase the risk of adverse
effects. The body re-equilibrates over time, but the acute rise can be clinically significant.
Q4: A drug with a narrow therapeutic index requires serum concentration monitoring.
Which of the following is the best example of such a medication?
A. Amoxicillin (wide therapeutic index, no monitoring needed)
B. Digoxin (narrow therapeutic index, requires serum level monitoring) [CORRECT]
C. Acetaminophen (wide therapeutic index at therapeutic doses)
D. Loratadine (wide therapeutic index, OTC)
Correct Answer: B
Rationale: Therapeutic index = TD50/ED50 (toxic dose in 50% / effective dose in 50%). Drugs with
narrow TI require serum monitoring because the difference between therapeutic and toxic doses is
small. Examples: digoxin, warfarin, lithium, phenytoin, vancomycin, aminoglycosides, theophylline.
Wide-TI drugs (penicillins, acetaminophen at therapeutic doses, statins) do not require routine
monitoring.
Q5: A patient receives a loading dose of phenytoin to rapidly achieve therapeutic serum
concentration. The pharmacokinetic principle supporting the loading dose is:
A. Loading dose = (target plasma concentration × volume of distribution) /
bioavailability; it saturates tissue compartments to achieve therapeutic levels
without waiting 4–5 half-lives [CORRECT]
B. Loading dose = clearance × maintenance dose
C. Loading dose = half-life × elimination rate
D. Loading dose is independent of volume of distribution
Correct Answer: A
Rationale: Loading dose = (Cp_target × Vd) / F, where Cp_target is desired plasma concentration, Vd
is volume of distribution, and F is bioavailability. The loading dose rapidly fills the apparent volume of
distribution to achieve therapeutic concentration, bypassing the 4–5 half-life wait for steady state. After
the loading dose, maintenance dose equals elimination rate to sustain steady state.
Q6: A drug binds reversibly to the same receptor site as the endogenous ligand,
produces no intrinsic activity, and its blockade can be overcome by increasing the
agonist dose. This drug is best classified as:
A. Competitive antagonist—binds reversibly at the agonist site, blocking action; effect
can be overcome by increasing agonist concentration (rightward shift of
dose-response curve with no change in Emax) [CORRECT]
B. Noncompetitive antagonist—binds irreversibly at the receptor
C. Partial agonist—produces submaximal effect
D. Inverse agonist—reduces constitutive receptor activity
Correct Answer: A
Chamberlain University — College of Nursing Page 2
,NR 565 Advanced Pharmacology Midterm Exam Review | Chamberlain (2026/2027)
Rationale: A competitive antagonist binds reversibly to the same receptor site as the agonist but has no
intrinsic activity, blocking agonist action. The blockade can be overcome by increasing agonist
concentration (rightward shift of dose-response curve with no change in Emax). Examples: naloxone
(mu-opioid), propranolol (beta-antagonist), losartan (AT1 antagonist). Noncompetitive antagonists
reduce Emax and cannot be overcome.
Q7: Which statement best distinguishes potency from efficacy in dose-response
pharmacology?
A. Potency is the dose or concentration needed to produce a defined effect (lower
EC50 = higher potency); efficacy is the maximum effect a drug can produce (Emax)
at any dose [CORRECT]
B. Potency and efficacy are interchangeable concepts
C. Potency refers to maximum effect; efficacy refers to dose required
D. Potency is determined by receptor density; efficacy is independent of intrinsic activity
Correct Answer: A
Rationale: Potency is the dose or concentration required to produce a defined effect (typically
EC50—effective concentration for 50% of maximum effect); a lower EC50 means higher potency.
Efficacy is the maximum effect (Emax) a drug can produce at any dose, reflecting intrinsic activity. A
drug can be highly potent but have low efficacy (e.g., partial agonists). Clinical decisions often depend
more on efficacy than potency.
Q8: A patient on metoprolol for hypertension abruptly discontinues the drug and
develops rebound tachycardia, hypertension, and angina. The pharmacodynamic
mechanism is:
A. Chronic beta-receptor antagonism upregulates beta receptors; abrupt cessation
exposes the upregulated receptors to endogenous catecholamines, producing
exaggerated sympathetic response (rebound phenomenon) [CORRECT]
B. Pharmacokinetic tolerance from enzyme induction
C. Idiosyncratic allergic reaction
D. Direct catecholamine release from adrenal medulla
Correct Answer: A
Rationale: Chronic receptor antagonism causes compensatory upregulation (increased receptor
number and sensitivity). When the antagonist is abruptly discontinued, endogenous catecholamines
stimulate the upregulated receptors, producing exaggerated response (rebound tachycardia,
hypertension, angina, arrhythmias). Beta-blockers must be tapered gradually over 1–2 weeks. Similar
upregulation occurs with clonidine (rebound hypertension) and SSRIs (discontinuation syndrome).
Q9: A patient receives IV theophylline for COPD. The drug follows zero-order
(Michaelis-Menten) kinetics at therapeutic doses. Which statement best describes this
pharmacokinetic property?
A. A constant amount of drug is eliminated per unit time regardless of plasma
concentration because metabolic enzymes are saturated; small dose increases can
produce disproportionate concentration increases and toxicity [CORRECT]
B. A constant fraction of drug is eliminated per unit time; half-life is constant
C. Elimination rate is proportional to plasma concentration
D. Half-life decreases with increasing dose
Correct Answer: A
Chamberlain University — College of Nursing Page 3
, NR 565 Advanced Pharmacology Midterm Exam Review | Chamberlain (2026/2027)
Rationale: In zero-order (capacity-limited, Michaelis-Menten) kinetics, a constant AMOUNT of drug is
eliminated per unit time because elimination enzymes are saturated. Examples: theophylline, phenytoin
(above therapeutic range), ethanol, high-dose aspirin. Clinical implication: small dose increases can
produce large, unpredictable rises in plasma concentration and toxicity. In contrast, first-order kinetics
eliminates a constant FRACTION per unit time with predictable half-life.
Q10: A patient develops Stevens-Johnson syndrome after starting allopurinol.
According to the Rawlins-Thompson classification, this adverse drug reaction (ADR) is
best categorized as which type?
A. Type B (bizarre) reaction—idiosyncratic, unpredictable, non-dose-dependent, often
immune-mediated (SJS, TEN, anaphylaxis) [CORRECT]
B. Type A (augmented) reaction—dose-dependent exaggeration of pharmacologic effect
C. Type C (chronic) reaction—cumulative dose effect
D. Type D (delayed) reaction—teratogenic or carcinogenic
Correct Answer: A
Rationale: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are Type B (bizarre,
idiosyncratic) ADRs—unpredictable, non-dose-dependent, immune-mediated reactions. Strongly
associated with HLA alleles (e.g., HLA-B*5801 with allopurinol in Southeast Asian populations). Type A
(augmented) reactions are dose-dependent extensions of pharmacologic effect (e.g., bleeding with
anticoagulants). Type C is chronic/cumulative; Type D is delayed.
Q11: A drug's volume of distribution (Vd) is calculated as 4 L. Which interpretation
best describes the drug's distribution pattern?
A. Vd approximates plasma volume, indicating the drug is largely confined to the
intravascular space (typical of large or highly protein-bound molecules like warfarin
or heparin) [CORRECT]
B. Vd indicates extensive tissue distribution throughout total body water
C. Vd indicates sequestration in fat
D. Vd is irrelevant to dosing decisions
Correct Answer: A
Rationale: Volume of distribution (Vd) is a theoretical volume relating drug dose to plasma
concentration. A Vd of ~3–5 L suggests confinement to plasma (intravascular space), typical of large
molecules (heparin, antibodies) or highly protein-bound drugs (warfarin). Vd of ~15–18 L suggests
extracellular fluid distribution; Vd of ~42 L suggests total body water; Vd >100 L suggests extensive
tissue binding/sequestration (digoxin, amiodarone, tricyclics). Vd influences loading dose calculation
and dialyzability.
Q12: A patient receiving IV heparin develops major bleeding. Protamine sulfate is
administered. Which type of pharmacologic antagonism best describes this
interaction?
A. Chemical (pharmaceutical) antagonism—protamine (positively charged) binds
ionically to heparin (negatively charged), forming an inactive complex that
neutralizes heparin's anticoagulant effect [CORRECT]
B. Physiologic antagonism—protamine activates opposing pathways
C. Competitive receptor antagonism at heparin receptors
D. Pharmacokinetic antagonism via enzyme induction
Correct Answer: A
Chamberlain University — College of Nursing Page 4
NR 565 / NR565 ADVANCED PHARMACOLOGY MIDTERM EXAM
REVIEW | ALREADY RATED A | LATEST, 2026/2027 |
CHAMBERLAIN COLLEGE
Chamberlain University — College of Nursing
Aligned with NR565 Advanced Pharmacology Course Syllabus, AACN Essentials of Master's Education, and
Advanced Practice Pharmacotherapeutics Standards (2026/2027 Edition)
Total Questions: 130 | Sections: 11 | Cognitive Mix: 25% Recall, 50% Application, 25% Analysis
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: An advanced practice nurse is reviewing a drug with a high hepatic extraction ratio
given orally. Which characteristic best describes the clinical consequence of this
property?
A. Oral bioavailability is low because of extensive hepatic first-pass metabolism;
changes in hepatic blood flow or enzyme activity can markedly alter serum
concentrations [CORRECT]
B. The drug is completely absorbed and achieves predictable serum levels regardless of hepatic
function
C. The drug is eliminated primarily unchanged by the kidney and requires no hepatic
consideration
D. Half-life is prolonged because hepatic enzymes are saturated at therapeutic doses
Correct Answer: A
Rationale: High-extraction-ratio drugs (e.g., propranolol, morphine, lidocaine, nitroglycerin) are
extensively removed by the liver during first-pass through the portal circulation, resulting in low oral
bioavailability. Changes in hepatic blood flow (e.g., heart failure) or enzyme activity (CYP
inducers/inhibitors) can markedly alter serum concentrations, requiring dose adjustment.
Q2: A drug has a half-life of 10 hours. Approximately what percentage of the drug
remains in the body 30 hours after the last dose (assuming first-order kinetics)?
A. 50% (one half-life)
B. 25% (two half-lives)
C. 12.5% (three half-lives) [CORRECT]
D. 6.25% (four half-lives)
Correct Answer: C
Rationale: After one half-life 50% remains, after two half-lives 25% remains, after three half-lives
12.5% remains, after four half-lives 6.25% remains. Thirty hours represents three half-lives for a drug
with a 10-hour half-life (30 ÷ 10 = 3). Steady state is achieved in approximately 4–5 half-lives.
Q3: Which statement best explains why a drug with high protein binding may require
cautious co-administration with another highly protein-bound drug?
A. Displacement from binding sites can transiently increase the free,
pharmacologically active fraction, potentially increasing effect or toxicity
[CORRECT]
B. Protein binding increases renal filtration of the drug
Chamberlain University — College of Nursing Page 1
,NR 565 Advanced Pharmacology Midterm Exam Review | Chamberlain (2026/2027)
C. Protein-bound drug is more readily metabolized by the liver
D. Protein binding eliminates the risk of drug interactions
Correct Answer: A
Rationale: Only unbound (free) drug is pharmacologically active and available for metabolism and
elimination. When two highly protein-bound drugs compete for binding sites (e.g., warfarin +
sulfamethoxazole), displacement can transiently raise the free fraction and increase the risk of adverse
effects. The body re-equilibrates over time, but the acute rise can be clinically significant.
Q4: A drug with a narrow therapeutic index requires serum concentration monitoring.
Which of the following is the best example of such a medication?
A. Amoxicillin (wide therapeutic index, no monitoring needed)
B. Digoxin (narrow therapeutic index, requires serum level monitoring) [CORRECT]
C. Acetaminophen (wide therapeutic index at therapeutic doses)
D. Loratadine (wide therapeutic index, OTC)
Correct Answer: B
Rationale: Therapeutic index = TD50/ED50 (toxic dose in 50% / effective dose in 50%). Drugs with
narrow TI require serum monitoring because the difference between therapeutic and toxic doses is
small. Examples: digoxin, warfarin, lithium, phenytoin, vancomycin, aminoglycosides, theophylline.
Wide-TI drugs (penicillins, acetaminophen at therapeutic doses, statins) do not require routine
monitoring.
Q5: A patient receives a loading dose of phenytoin to rapidly achieve therapeutic serum
concentration. The pharmacokinetic principle supporting the loading dose is:
A. Loading dose = (target plasma concentration × volume of distribution) /
bioavailability; it saturates tissue compartments to achieve therapeutic levels
without waiting 4–5 half-lives [CORRECT]
B. Loading dose = clearance × maintenance dose
C. Loading dose = half-life × elimination rate
D. Loading dose is independent of volume of distribution
Correct Answer: A
Rationale: Loading dose = (Cp_target × Vd) / F, where Cp_target is desired plasma concentration, Vd
is volume of distribution, and F is bioavailability. The loading dose rapidly fills the apparent volume of
distribution to achieve therapeutic concentration, bypassing the 4–5 half-life wait for steady state. After
the loading dose, maintenance dose equals elimination rate to sustain steady state.
Q6: A drug binds reversibly to the same receptor site as the endogenous ligand,
produces no intrinsic activity, and its blockade can be overcome by increasing the
agonist dose. This drug is best classified as:
A. Competitive antagonist—binds reversibly at the agonist site, blocking action; effect
can be overcome by increasing agonist concentration (rightward shift of
dose-response curve with no change in Emax) [CORRECT]
B. Noncompetitive antagonist—binds irreversibly at the receptor
C. Partial agonist—produces submaximal effect
D. Inverse agonist—reduces constitutive receptor activity
Correct Answer: A
Chamberlain University — College of Nursing Page 2
,NR 565 Advanced Pharmacology Midterm Exam Review | Chamberlain (2026/2027)
Rationale: A competitive antagonist binds reversibly to the same receptor site as the agonist but has no
intrinsic activity, blocking agonist action. The blockade can be overcome by increasing agonist
concentration (rightward shift of dose-response curve with no change in Emax). Examples: naloxone
(mu-opioid), propranolol (beta-antagonist), losartan (AT1 antagonist). Noncompetitive antagonists
reduce Emax and cannot be overcome.
Q7: Which statement best distinguishes potency from efficacy in dose-response
pharmacology?
A. Potency is the dose or concentration needed to produce a defined effect (lower
EC50 = higher potency); efficacy is the maximum effect a drug can produce (Emax)
at any dose [CORRECT]
B. Potency and efficacy are interchangeable concepts
C. Potency refers to maximum effect; efficacy refers to dose required
D. Potency is determined by receptor density; efficacy is independent of intrinsic activity
Correct Answer: A
Rationale: Potency is the dose or concentration required to produce a defined effect (typically
EC50—effective concentration for 50% of maximum effect); a lower EC50 means higher potency.
Efficacy is the maximum effect (Emax) a drug can produce at any dose, reflecting intrinsic activity. A
drug can be highly potent but have low efficacy (e.g., partial agonists). Clinical decisions often depend
more on efficacy than potency.
Q8: A patient on metoprolol for hypertension abruptly discontinues the drug and
develops rebound tachycardia, hypertension, and angina. The pharmacodynamic
mechanism is:
A. Chronic beta-receptor antagonism upregulates beta receptors; abrupt cessation
exposes the upregulated receptors to endogenous catecholamines, producing
exaggerated sympathetic response (rebound phenomenon) [CORRECT]
B. Pharmacokinetic tolerance from enzyme induction
C. Idiosyncratic allergic reaction
D. Direct catecholamine release from adrenal medulla
Correct Answer: A
Rationale: Chronic receptor antagonism causes compensatory upregulation (increased receptor
number and sensitivity). When the antagonist is abruptly discontinued, endogenous catecholamines
stimulate the upregulated receptors, producing exaggerated response (rebound tachycardia,
hypertension, angina, arrhythmias). Beta-blockers must be tapered gradually over 1–2 weeks. Similar
upregulation occurs with clonidine (rebound hypertension) and SSRIs (discontinuation syndrome).
Q9: A patient receives IV theophylline for COPD. The drug follows zero-order
(Michaelis-Menten) kinetics at therapeutic doses. Which statement best describes this
pharmacokinetic property?
A. A constant amount of drug is eliminated per unit time regardless of plasma
concentration because metabolic enzymes are saturated; small dose increases can
produce disproportionate concentration increases and toxicity [CORRECT]
B. A constant fraction of drug is eliminated per unit time; half-life is constant
C. Elimination rate is proportional to plasma concentration
D. Half-life decreases with increasing dose
Correct Answer: A
Chamberlain University — College of Nursing Page 3
, NR 565 Advanced Pharmacology Midterm Exam Review | Chamberlain (2026/2027)
Rationale: In zero-order (capacity-limited, Michaelis-Menten) kinetics, a constant AMOUNT of drug is
eliminated per unit time because elimination enzymes are saturated. Examples: theophylline, phenytoin
(above therapeutic range), ethanol, high-dose aspirin. Clinical implication: small dose increases can
produce large, unpredictable rises in plasma concentration and toxicity. In contrast, first-order kinetics
eliminates a constant FRACTION per unit time with predictable half-life.
Q10: A patient develops Stevens-Johnson syndrome after starting allopurinol.
According to the Rawlins-Thompson classification, this adverse drug reaction (ADR) is
best categorized as which type?
A. Type B (bizarre) reaction—idiosyncratic, unpredictable, non-dose-dependent, often
immune-mediated (SJS, TEN, anaphylaxis) [CORRECT]
B. Type A (augmented) reaction—dose-dependent exaggeration of pharmacologic effect
C. Type C (chronic) reaction—cumulative dose effect
D. Type D (delayed) reaction—teratogenic or carcinogenic
Correct Answer: A
Rationale: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are Type B (bizarre,
idiosyncratic) ADRs—unpredictable, non-dose-dependent, immune-mediated reactions. Strongly
associated with HLA alleles (e.g., HLA-B*5801 with allopurinol in Southeast Asian populations). Type A
(augmented) reactions are dose-dependent extensions of pharmacologic effect (e.g., bleeding with
anticoagulants). Type C is chronic/cumulative; Type D is delayed.
Q11: A drug's volume of distribution (Vd) is calculated as 4 L. Which interpretation
best describes the drug's distribution pattern?
A. Vd approximates plasma volume, indicating the drug is largely confined to the
intravascular space (typical of large or highly protein-bound molecules like warfarin
or heparin) [CORRECT]
B. Vd indicates extensive tissue distribution throughout total body water
C. Vd indicates sequestration in fat
D. Vd is irrelevant to dosing decisions
Correct Answer: A
Rationale: Volume of distribution (Vd) is a theoretical volume relating drug dose to plasma
concentration. A Vd of ~3–5 L suggests confinement to plasma (intravascular space), typical of large
molecules (heparin, antibodies) or highly protein-bound drugs (warfarin). Vd of ~15–18 L suggests
extracellular fluid distribution; Vd of ~42 L suggests total body water; Vd >100 L suggests extensive
tissue binding/sequestration (digoxin, amiodarone, tricyclics). Vd influences loading dose calculation
and dialyzability.
Q12: A patient receiving IV heparin develops major bleeding. Protamine sulfate is
administered. Which type of pharmacologic antagonism best describes this
interaction?
A. Chemical (pharmaceutical) antagonism—protamine (positively charged) binds
ionically to heparin (negatively charged), forming an inactive complex that
neutralizes heparin's anticoagulant effect [CORRECT]
B. Physiologic antagonism—protamine activates opposing pathways
C. Competitive receptor antagonism at heparin receptors
D. Pharmacokinetic antagonism via enzyme induction
Correct Answer: A
Chamberlain University — College of Nursing Page 4
